EULEXIN (flutamide) Capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B₂-C and Stage D₂ metastatic carcinoma of the prostate.

Stage B₂-C Prostatic Carcinoma

Treatment with EULEXIN (flutamide) Capsules and the LHRH agonist should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.

Stage D₂ Metastatic Carcinoma

To achieve benefit from treatment, EULEXIN (flutamide) Capsules should be initiated with the LHRH agonist and continued until progression.

The recommended dosage is 2 capsules 3 times a day at 8-hour intervals for a total daily dose of 750 mg.

EULEXIN (flutamide) Capsules, 125 mg, are available as opaque, two- toned brown capsules, imprinted with "Schering 525†. They are supplied as follows:

NDC 0085-0525-05 - Bottles of 500

NDC 0085-0525-03 - Unit Dose packages of 100 (10 x 10†s)

NDC 0085-0525-06 - Bottles of 180

Store between 2^o and 30^o C (36^o and 86^o F). Protect the Unit Dose packages from excessive moisture.

Last reviewed on RxList: 12/28/2004
This monograph has been modified to include the generic and brand name in many instances.